Literature DB >> 11369873

Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein.

Una Lazdina1, Catharina Hultgren1, Lars Frelin1, Margaret Chen1, Karin Lodin1, Ola Weiland1, Geert Leroux-Roels2, Juan A Quiroga3, Darrell L Peterson4, David R Milich5, Matti Sällberg1.   

Abstract

The non-structural 3 (NS3) protein is one of the most conserved proteins of hepatitis C virus, and T helper 1 (Th1)-like responses to NS3 in humans correlate with clearance of infection. Several studies have proposed that DNA-based immunizations are highly immunogenic and prime Th1-like responses, although few head-to-head comparisons with exogenous protein immunizations have been described. A full-length NS3/NS4A gene was cloned in eukaryotic vectors with expression directed to different subcellular compartments. Inbred mice were immunized twice in regenerating tibialis anterior (TA) muscles with either plasmid DNA or recombinant NS3 (rNS3). After two 100 micrograms DNA immunizations, specific antibody titres of up to 12960 were detected at week 5, dominated by IgG2a and IgG2b. NS3-specific CD4(+) T cell responses in DNA-immunized mice peaked at day 13, as measured by proliferation and IL-2 and IFN-gamma production. Mice immunized with 1-10 micrograms rNS3 without adjuvant developed antibody titres comparable to those of the DNA-immunized mice, but dominated instead by IgG1. CD4(+) T cell responses in these mice showed peaks of IL-2 response at day 3 and IL-6 and IFN-gamma responses at day 6. With adjuvant, rNS3 was around 10-fold more immunogenic with respect to speed and magnitude of the immune responses. Thus, immunization with rNS3 in adjuvant is superior to DNA immunization with respect to kinetics and quantity in priming specific antibodies and CD4(+) T cells. However, as a DNA immunogen, NS3 elicits stronger Th1-like immune responses, whereas rNS3 primes a mixed Th1/Th2-like response regardless of the route, dose or adjuvant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369873     DOI: 10.1099/0022-1317-82-6-1299

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Relation between viral fitness and immune escape within the hepatitis C virus protease.

Authors:  J Söderholm; G Ahlén; A Kaul; L Frelin; M Alheim; C Barnfield; P Liljeström; O Weiland; D R Milich; R Bartenschlager; M Sällberg
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

2.  DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein.

Authors:  Benjamin E Simon; Kenneth A Cornell; Tina R Clark; Sunwen Chou; Hugo R Rosen; Ronald A Barry
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

3.  The Distinct Role of Small Heat Shock Protein 20 on HCV NS3 Expression in HEK-293T Cell Line.

Authors:  Marzieh Basirnejad; Azam Bolhassani; Seyed Mehdi Sadat
Journal:  Avicenna J Med Biotechnol       Date:  2018 Jul-Sep

4.  Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Authors:  G Ahlén; E Derk; M Weiland; J Jiao; N Rahbin; S Aleman; D L Peterson; K Pokrovskaja; D Grandér; L Frelin; M Sällberg
Journal:  Gut       Date:  2008-08-08       Impact factor: 23.059

5.  Construction and Immunogenicity Analysis of Hepatitis C Virus (HCV) Truncated Non-Structural Protein 3 (NS3) Plasmid Vaccine.

Authors:  Mohammad-Hassan Pouriayevali; Taravat Bamdad; Mohammad-Reza Aghasadeghi; Seyed Mehdi Sadat; Farzaneh Sabahi
Journal:  Jundishapur J Microbiol       Date:  2016-03-19       Impact factor: 0.747

6.  Investigation of the Immunomodulatory effect of Berberis vulgaris on core-pulsed dendritic cell vaccine.

Authors:  Doaa A Ghareeb; Eiman H Elwakeel; Rowaida Khalil; Mina S Aziz; Maha A El Demellawy
Journal:  BMC Complement Altern Med       Date:  2016-08-30       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.